Form 8-K - Current report:
SEC Accession No. 0001193125-26-257379
Filing Date
2026-06-04
Accepted
2026-06-04 16:05:19
Documents
13
Period of Report
2026-06-03
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d57321d8k.htm   iXBRL 8-K 57640
2 EX-3.1 d57321dex31.htm EX-3.1 7134
3 EX-3.2 d57321dex32.htm EX-3.2 93366
  Complete submission text file 0001193125-26-257379.txt   308590

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nerv-20260603.xsd EX-101.SCH 3204
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nerv-20260603_lab.xml EX-101.LAB 17978
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nerv-20260603_pre.xml EX-101.PRE 11274
17 EXTRACTED XBRL INSTANCE DOCUMENT d57321d8k_htm.xml XML 3752
Mailing Address 1500 DISTRICT AVENUE BURLINGTON MA 01803
Business Address 1500 DISTRICT AVENUE BURLINGTON MA 01803 617-600-7373
Minerva Neurosciences, Inc. (Filer) CIK: 0001598646 (see all company filings)

EIN.: 260784194 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36517 | Film No.: 261064893
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)